AMRXのニュース
Amneal Pharmaceuticals, Inc. (AMRX) Q1 2023 Earnings Call Transcript 2023/05/05 17:25:23 Seeking Alpha
Amneal Pharmaceuticals, Inc. (NYSE:NYSE:AMRX) Q1 2023 Earnings Conference Call May 5, 2023 8:30 AM ETCompany ParticipantsTony DiMeo - Head-Investor RelationsChirag Patel - President &…
Amneal Pharmaceuticals, Inc. 2023 Q1 - Results - Earnings Call Presentation 2023/05/05 15:43:41 Seeking Alpha
The following slide deck was published by Amneal Pharmaceuticals, Inc.
Amneal Pharma Q1 Exceeds Consensus View On Strength In Complex Generics Portfolio 2023/05/05 13:51:42 Benzinga
Amneal Pharmaceuticals Inc (NYSE: AMRX ) reported first-quarter FY23 revenue of $557.54 million, an increase of 12% year over year, beating the consensus of $537.31 million . Adjusted EPS was $0.12, beating the consensus of $0.10, and was flat Y/Y. The increase was driven by growth across all … Full story available on Benzinga.com
Recap: Amneal Pharmaceuticals Q1 Earnings 2023/05/05 11:02:25 Benzinga
Amneal Pharmaceuticals (NYSE: AMRX ) reported its Q1 earnings results on Friday, May 5, 2023 at 06:00 AM. Here''s what investors need to know about the announcement. Earnings Amneal Pharmaceuticals beat estimated earnings by 20.0%, reporting an EPS of $0.12 versus an estimate of $0.1. Revenue was up $59.91 million from the same period last … Full story available on Benzinga.com
Amneal: Q1 Earnings Snapshot 2023/05/05 10:09:29 WTOP
BRIDGEWATER, N.J. (AP) — BRIDGEWATER, N.J. (AP) — Amneal Pharmaceuticals, Inc. (AMRX) on Friday reported a loss of $6.9 million…
Amneal to Report Fourth Quarter and Full Year 2022 Results on March 2, 2023 2023/01/31 13:00:00 Business Wire
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its fourth quarter and full year 2022 financial results on Thursday March 2, 2023, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time on March 2, 2023. The financial results and live webcast will be accessible through the Investor Relations section of the Company''s website at https://invest
Intercept Surges To Four-Month High After Staving Off Amneal''s Generic For 11 Years 2023/01/25 18:15:30 Investor''s Business Daily
Intercept reached a settlement with Amneal that delays a generic version of its only product. In response, ICPT stock surged Wednesday.
ICPT stock gains after patent settlement with Amneal (NASDAQ:ICPT) 2023/01/25 17:44:58 Seeking Alpha
Intercept Pharma (ICPT) shares gained Wednesday after a deal with generic drugmaker Amneal Pharma (AMRX) to settle a patent dispute over liver drug Ocaliva. Read the full story here.
Amneal: Downside Risk Persists (NYSE:AMRX) 2023/01/23 17:29:39 Seeking Alpha
Inability to efficiently market new drugs might put significant pressure on Amneal''s margins. Read more to see AMRX stock''s growth opportunities and risks.
Amneal Pharmaceuticals Inc. (NYSE: AMRX): The Metrics That Matter Right Now 2023/01/14 17:00:00 Stocks Register
Amneal Pharmaceuticals Inc. (NYSE:AMRX) price on Friday, January 13, fall -0.45% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $2.22. A look at the stock’s price movement, the close in the last trading session was $2.23, moving within a range at $2.18 and $2.265. The beta value … Amneal Pharmaceuticals Inc. (NYSE: AMRX): The Metrics That Matter Right Now Read More »
Amneal Pharma begins commercial operations in India 2022/10/11 04:53:58 Express Pharma
Appoints Shyamakant Giri as Managing Director and President for India Business and Emerging Markets The post Amneal Pharma begins commercial operations in India appeared first on Express Pharma .
New Jersey-based Amneal Pharma starts mfg operations for Indian market 2022/10/10 10:42:00 Business Standard
The firm already has manufacturing units in four Indian cities, all of which are focused on the export market
Amneal Pharma starts commercial operations in India 2022/10/10 09:41:34 The Hindu BusinessLine
Appoints Shyamakant Giri, Managing Director and President, India Business and Emerging Markets
Amneal Launches First Biosimilar with ALYMSYS (bevacizumab-maly) in the United States 2022/10/03 20:05:00 Wallstreet:Online
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced the commercial launch of ALYMSYS (bevacizumab-maly), a biosimilar referencing Avastin. ALYMSYS is a vascular endothelial growth factor inhibitor used in oncology. This product was developed by mAbxience, a global biotech company with over a decade of experience in the development, manufacture, and commercialization
Do investors need to be concerned about Amneal Pharmaceuticals Inc. (AMRX)? 2022/09/21 13:48:00 US Post News
Amneal Pharmaceuticals Inc. (NYSE:AMRX) closed Tuesday at $2.29 per share, up from $2.27 a day earlier. While Amneal Pharmaceuticals Inc. has overperformed by 0.88%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, AMRX fell by -53.74%, with highs and lows ranging from $5.99 to $2.15, whereas […]